Denali Therapeutics (DNLI) Treasury Shares (2017 - 2026)

Denali Therapeutics (DNLI) has 10 years of Treasury Shares data on file, last reported at $6.9 million in Q1 2026.

• Treasury Shares for Q1 2026 came in at $6.9 million, up 41.8% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.9 million (up 41.8% YoY), and the FY2025 annual result was $5.1 million, up 24.13% from the prior year.
• Treasury Shares rose to $6.9 million in Q1 2026 per DNLI's latest filing, from $5.1 million in the prior quarter.
• Over five years, Treasury Shares peaked at $6.9 million in Q1 2026 and troughed at $2.9 million in Q2 2022.
• A 5-year average of $4.2 million and a median of $4.0 million in 2024 frame the typical range for Treasury Shares.
• The sharpest annual moves came in 2024 and 2026: Treasury Shares advanced 7.43% in 2024, then soared 41.8% in 2026.
• A 5-year view of Treasury Shares shows it stood at $3.3 million in 2022, then grew by 9.14% to $3.6 million in 2023, then advanced by 13.57% to $4.1 million in 2024, then advanced by 24.13% to $5.1 million in 2025, then surged by 34.18% to $6.9 million in 2026.
• Business Quant data shows DNLI's Treasury Shares at $6.9 million in Q1 2026, $5.1 million in Q4 2025, and $5.2 million in Q3 2025.